Atherosclerosis vessel wall inflammation
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy controls * Adults (either gender) * 18 years * Willing and able to participate in study protocol;Splenectomized patients * Adults (either gender) * 18 years * History of traumatic splenectomy * Participated in scientific research at the AMC previously and have given permission via informed consent to be willing to be contacted for other research at the AMC in the future. * Willing and able to participate in study protocol;Cardiovascular patients * Adults (either gender) * 18 years * Cardiovascular patients are recognized by atherosclerotic cardiovascular disease, thus atherosclerosis in either coronary, carotid, aortic and/or peripheral arteries. The above needs to be documented in the history of the patient by one or more of the following: o History of coronary heart disease (angina pectoris, myocardial infarction), cerebrovascular disease (stroke), peripheral arterial disease (claudicatio intermittens). o Objective diagnostic (imaging) examinations, including exercise treadmill test, stress echocardiography, myocardial perfusion scintigraphy, right or left common carotid intima-media thickness (CIMT) by ultrasound > 75th percentile by American Society of Echocardiography, presence of carotid plaque by carotid ultrasound (focal thickening > 50% or CIMT > 1.5 mm), coronary artery calcium score > 100 Agatston units in patients
Exclusion criteria
Exclusion criteria: Healthy controls are not eligible if they meet one of the criteria listed below: * Any known systemic chronic disorders/medical condition or chronic use of systemic medication that could interfere with the conduct of the study in the opinion of the investigator. * Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.;Splenectomized patients are not eligible if they meet one of the criteria listed below: * History of cardiovascular diseases (including atherosclerotic CVD, heartfailure, etc) or cardiovascular medication such as use of beta blocker therapy, calciumantagonists and CYP2D6 inhibitors. * Auto-immune disease/vasculitis, other active inflammatory diseases, proven or suspected bacterial infections. Recent (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameter 1. Changes in monocyte count and differentiation after LBNP in healthy volunteers | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters 2. Changes in monocyte count and differentiation after LBNP in splenectomized patients or patients with advanced cardiovascular disease. 3. Differences between monocyte behaviour and characteristics in healthy volunteers, splenectomized patients and patients with advanced cardiovascular disease. 4. Suppression of monocyte release via inhibition of nervous signaling pathway via B receptor blockade. | — |
Countries
Netherlands
Outcome results
None listed